The first patient has entered the Phase II/III trial of ST-02, Sustained Therapeutic’s innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC).
Sustained Therapeutics Announces First Patient for Cancer Trial Read More »
A federal court in Texas ruled regulators exceeded their authority in limiting providers’ use of online tracking technologies.
Federal judge sides with providers, nixes online tracker guidance Read More »
If the deal goes through, it will be Risant’s second acquisition after the nonprofit hospital venture was launched last year.
Kaiser-owned Risant to buy North Carolina system Cone Health Read More »
At the American Diabetes Association meeting, Insulet shared study results showing improvements in blood glucose and quality of life.
Insulet seeks label expansion of Omnipod 5 for Type 2 diabetes Read More »
En muchas ocasiones pensamos que la ortodoncia solo sirve para mejorar estéticamente nuestra sonrisa. Más allá de la cuestión estética, la realidad es que este tratamiento ayuda a la prevención y corrección de muchos problemas bucodentales. …
The Fifth Circuit Court of Appeals’ decision Friday is a win for the upwards of 150 million people that receive health insurance through their employers. However, it paves the way for future lawsuits from opponents of the ACA.
Kimberley Elting will end her eight-year stint at the company in July, continuing Orthofix’s recent trend of executive turnover.
Orthofix’s president of global orthopedics resigns Read More »
Cardinal listed more than 500 catalog numbers in its recall notice and told customers to remove and discard the syringes.
Cardinal Health recalls procedure kits over plastic syringes made in China Read More »
Alnylam’s Amvuttra reduced the risk of all-cause death or recurrent cardiovascular events by at least 28% in patients with transthyretin amyloidosis with cardiomyopathy, the company announced Monday.
Alnylam Aces Phase III Cardio Trial, Eyes Label Expansion for RNAi Therapy Read More »
Matinas BioPharma Holdings, Inc. announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales.
